Recreational Drugs Can More than Double Risk of Stroke, Study Suggests

Why It Matters

The study quantifies a preventable cardiovascular hazard, prompting urgent public‑health and clinical attention to illicit drug use as a major stroke risk factor.

Key Takeaways

• Amphetamine use raises stroke risk by 122%.
• Cocaine users face 96% higher stroke risk.
• Cannabis linked to 37% increased stroke incidence.
• Under‑55 amphetamine users see near‑tripling stroke risk.
• Opioids show no significant stroke risk increase.

Pulse Analysis

The new meta‑analysis, published in the International Journal of Stroke, pooled data from 32 studies covering more than 100 million individuals to quantify the relationship between recreational drug use and cerebrovascular events. By comparing users of amphetamines, cocaine, cannabis and opioids with non‑users, the researchers identified markedly elevated odds ratios for stroke—122 % for amphetamines, 96 % for cocaine and 37 % for cannabis. The sheer size of the dataset lends statistical weight to the findings, while the inclusion of genetic predisposition analyses strengthens the argument that the substances themselves, rather than confounding health factors, drive the risk.

The physiological pathways linking these drugs to stroke are well documented. Amphetamines and cocaine trigger acute hypertension and vasoconstriction, creating conditions for both hemorrhagic and ischemic events, while cocaine accelerates atherosclerotic plaque formation. Cannabis, though often perceived as benign, also narrows cerebral vessels and may promote clotting. Notably, the study highlighted a near‑tripling of stroke risk among users under 55 who take amphetamines, underscoring that younger populations are not immune to drug‑induced vascular damage. Opioids, by contrast, showed no statistically significant association.

From a policy perspective, the results reinforce the need for targeted public‑health campaigns that frame illicit drug use as a preventable stroke risk factor. Healthcare providers should incorporate substance‑use screening into cardiovascular risk assessments, especially for younger adults. The findings also suggest that regulators could consider stricter controls on stimulant distribution and invest in harm‑reduction programs. Future research must explore dose‑response relationships and longitudinal outcomes to refine risk models, while clinicians await clearer guidelines on managing stroke risk in patients with active drug use.